2 research outputs found
Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of âreal-worldâ evidence
<p><b>Introduction</b>: Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological condition characterized by itchy wheals and/or angioedema of continuous or intermittent duration of âĽ6 weeks with a high burden of disease and impact on quality of life. Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of IgE to high affinity receptors, and is approved for the CIU/CSU indication. The objective of this systematic review was to evaluate and synthesize the evidence on the real-world effectiveness of omalizumab in CIU/CSU in daily clinical practice.</p> <p><b>Areas covered</b>: This review of 84 observational effectiveness studies covers treatments (dosing, medication use), clinical outcomes (treatment response, disease activity, quality of life), and safety.</p> <p><b>Expert opinion</b>: The clinical outcomes observed across studies underscore the real-world effectiveness of omalizumab in the management of CIU/CSU. Continued treatment may assist patients showing an initial response to achieve a complete treatment response. Response rates are aligned with observed changes in disease activity, symptom experience, and quality of life, and this across subtypes of CIU/CSU. The positive therapeutic profile is complemented by a positive safety profile. The real-world evidence summarized here points convincingly at the high degree of effectiveness of omalizumab in the treatment of CIU/CSU in daily clinical practice.</p
Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
<p><b>Article full text</b></p><p><br></p><p>The full text of this article can
be found here<b>.</b></p><p><a href="https://link.springer.com/article/10.1007/s13555-018-0225-6">https://link.springer.com/article/10.1007/s13555-018-0225-6</a></p><p></p><p></p><p><br></p><p><b>Provide enhanced content for this
article</b></p><p><br></p><p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âÂÂmailto:[email protected]âÂÂ"><b>[email protected]</b></a>.</p><p> </p><p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include,
but are not limited to:</p><p><br></p><p>⢠Slide decks</p><p>⢠Videos and animations</p><p>⢠Audio abstracts</p><p>⢠Audio slides</p><p>
</p><p> </p